 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
GLYCOGENESYS INC, (GLGS) Stock Rating Learn More
| Our Overall Rating on GLYCOGENESYS INC, GLGS is Not Available | | GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The companys lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It has also developed agricultural products, which are also based upon carbohydrate chemistries. The company was co-founded by David Platt in 1992 as IGG International, Inc. It changed its name to SafeScience, Inc. in 1998 and further changed its name to GlycoGenesys, Inc. in 2001. The company is based in Boston, Massachusetts. | | Our Not Available Rating on GLGS was issued on 12/02/2008 |
GLYCOGENESYS INC Technical Rating
|
|
|
|
